(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Investigating the Financial History of the World: A Succinct Outline - 22025 Was Another Exceptionally Hot Year
- 3Grasping the Commencement of Criminal Cases: An Extensive Outline
- 4CDC advisory panel delays vote on hepatitis B vaccines after unruly meeting
- 5Damaged Shenzhou-20 spacecraft to return to Earth uncrewed for inspection
- 4 Coolers for Present day Kitchens
- Winter storm warnings issued across Northeast as up to 9 inches of snow forecast; deadly atmospheric river in California snarls travel
- The 20 Most sultry Style of the Time
- Geomagnetic storm grounds launch of Mars space weather satellites
- ‘Extraordinary’ Iron Age war trumpet uncovered in England
- Merz visit highlights new strategic, and strained, Germany-Israel bond
- Flu surges across U.S. as doctor visits reach highest level since 1997
- Explainer-What has happened to the damaged spacecraft at China's space station?
- What are the health benefits of whole milk for kids?
